Fate Therapeutics Secures FDA IND Clearance for FT839, a Dual iPSC-Derived CAR T-Cell Candidate, with Phase 1/2a Trial Targeting Autoimmune Diseases and Hematologic Malignancies to Commence in H2 2026

July 19, 2026

GlobeNewswire USA

Overview

Fate Therapeutics announced FDA IND clearance for FT839, its iPSC-derived dual CAR T-cell product candidate. FT839 is designed to simultaneously target CD19 and CD38, aiming for comprehensive treatment across a range of autoimmune diseases and hematologic malignancies. A Phase 1/2 basket clinical trial is anticipated to begin in the second half of 2026. This dual CAR T-cell technology is expected to offer improved efficacy and reduced relapse risk compared to single-target therapies, potentially establishing a new treatment paradigm.

In Depth

Key Findings

On July 9, 2026, Fate Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FT839, an iPSC-derived dual CAR T-cell product candidate. This clearance enables Fate Therapeutics to initiate a Phase 1/2 basket clinical trial for FT839 in the second half of 2026, targeting both autoimmune diseases and hematologic malignancies.

Technical / Clinical Details

FT839 is an innovative therapeutic candidate manufactured from Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) platform. This cell therapy incorporates a ‘dual CAR’ design, engineered to simultaneously target two distinct cell surface antigens: CD19 and CD38. CD19 is widely expressed in B-cell malignancies and certain autoimmune disorders, while CD38 is a key target in plasma cell malignancies like multiple myeloma and specific autoimmune conditions. The dual-targeting strategy is intended to overcome treatment resistance often caused by antigen escape mechanisms, aiming for a broader and more durable therapeutic effect. The upcoming Phase 1/2 basket study will evaluate the safety, tolerability, and preliminary efficacy of FT839 across multiple disease cohorts.

Background & Context

CAR T-cell therapies have achieved remarkable success in hematologic cancers, but they face challenges in expanding to solid tumors and autoimmune diseases, as well as addressing relapses due to antigen escape. Off-the-shelf (allogeneic) iPSC-derived CAR T-cells offer the potential to circumvent the time-consuming and costly individualized manufacturing process of autologous therapies, thereby improving accessibility and reducing treatment burdens. Furthermore, dual CAR designs like FT839 aim to transcend the limitations of single-antigen therapies by eliciting more robust and comprehensive immune responses. This advancement marks a crucial step in the evolution of cell therapy technology, expanding into new disease areas and simultaneously enhancing both efficacy and accessibility.

Strategic Significance & Outlook

The IND clearance for FT839 represents a pivotal milestone in Fate Therapeutics’ iPSC-derived cell therapy pipeline. The planned initiation of clinical trials in late 2026 significantly broadens the therapeutic possibilities for both autoimmune diseases and hematologic malignancies. If the dual CAR strategy proves successful in the clinic, it has the potential to transform the standard of care for these conditions, offering patients novel therapies that provide durable responses. The upcoming data from these trials are highly anticipated by the scientific and investment communities.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.